Bavarian Nordic still hopes to find financing for Covid-19 vaccine

In spite of positive preclinical data, Bavarian Nordic maintains that the firm itself will not finance further studies after the first phase I/II study. The company remains optimistic, however, about the prospects of finding capital for the vaccine from external sources.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

While Bavarian Nordic's vaccine candidate against Covid-19 will soon enter into the first in-human phase I/II study, the Danish vaccine company is on the lookout for a partner to finance its further development and the process of taking the Covid-19 vaccine to market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading